Tiberius Claudius Verus

VERU ALERT: Bragar Eagel & Squire, P.C. is Investigating Veru Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, December 15, 2023
Class Action Lawsuit, Professional Services, Legal, NDA, Breast, Acute respiratory distress syndrome, Safety, Telephone, Complaint, Mortality, Patient, Fast track (FDA), Infection, FDA, Prostate cancer, Prostate Cancer Foundation, Jeanne Eagels, Aerospace, COVID-19, Standard of care, Trial of the century, Death, P.C, Form 10-Q, Fast Track, News, Cryptocurrency, Pharmaceutical industry, Tiberius Claudius Verus

Our investigation concerns whether the board of directors of Veru have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Veru have breached their fiduciary duties to the company.
  • Veru is primarily an oncology-based biopharmaceutical company that develops drugs for the management of breast and prostate cancers.
  • Veru had originally developed sabizabulin with the intention of using it as a treatment for prostate cancer.
  • At the time, there was no authorized or approved treatment for hospitalized patients with severe COVID-19 infections.

Veru Provides FDA Update on Request for Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for ARDS

Retrieved on: 
Thursday, March 2, 2023
Death, Agency, FDA, NDA, Public, Patient, HHS, Risk, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, COVID-19, EUA, Trial of the century, Office of Inspector General, U.S. Department of Health and Human Services, Therapy, Food, Pharmaceutical industry, Tiberius Claudius Verus

In communicating its decision, the FDA stated that despite the FDA declining to issue an EUA for sabizabulin at this time, the FDA remains committed to working with the Company for the development of sabizabulin.

Key Points: 
  • In communicating its decision, the FDA stated that despite the FDA declining to issue an EUA for sabizabulin at this time, the FDA remains committed to working with the Company for the development of sabizabulin.
  • Separately, the FDA also provided comments on a proposed confirmatory Phase 3 study protocol submitted by the Company for hospitalized moderate to severe COVID-19 patients at risk for ARDS and death that could support a new EUA authorization and/or NDA approval.
  • During our May 10, 2022 pre-EUA meeting with the FDA, the Agency indicated that our clinical data package was sufficient to support an EUA submission.
  • We lost 510 Americans to COVID-19 just yesterday despite existing FDA authorized and approved standard of care treatments.

VERU DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Veru Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, February 2, 2023
Class Action Lawsuit, Professional Services, Legal, NDA, Acute respiratory distress syndrome, Standard of care, Trial of the century, Form 10-Q, Breast, Tiberius Claudius Verus, Safety, P.C, Patient, Telephone, Jeanne Eagels, News, Fast track (FDA), Prostate cancer, Mortality, Aerospace, Person, Death, Prostate Cancer Foundation, FDA, Court, Steiner, COVID-19, Fast Track, Infection, EUA, Pharmaceutical industry

Investors have until February 3, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until February 3, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Veru is primarily an oncology-based biopharmaceutical company that develops drugs for the management of breast and prostate cancers.
  • Veru also develops medicines for COVID-19 and other diseases related to viral and acute respiratory distress syndrome (“ARDS”), and has two FDA-approved products for sexual health.
  • Veru had originally developed sabizabulin with the intention of using it as a treatment for prostate cancer.

Veru Inc. Sued By Block & Leviton LLP for Securities Law Violations

Retrieved on: 
Tuesday, January 10, 2023
COVID-19, EUA, District court, Certification, FDA, United States district court, Tiberius Claudius Verus, NDA, Food, Complaint, Pharmaceutical industry

BOSTON, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Block & Leviton LLP ( www.blockleviton.com ), a national securities litigation firm, announces that it has filed a class action lawsuit on behalf of shareholders against Veru Inc. (NASDAQ: VERU) and certain of its executives, for securities fraud.

Key Points: 
  • BOSTON, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Block & Leviton LLP ( www.blockleviton.com ), a national securities litigation firm, announces that it has filed a class action lawsuit on behalf of shareholders against Veru Inc. (NASDAQ: VERU) and certain of its executives, for securities fraud.
  • The complaint was brought in United States District Court for the Southern District of Florida and is captioned Ewing v. Veru Inc., et al., No.
  • A class has not yet been certified, and until certification occurs, you are not represented by an attorney.
  • Block & Leviton LLP is a firm dedicated to representing investors and maintaining the integrity of the country’s financial markets.

ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Veru, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action– VERU

Retrieved on: 
Friday, December 30, 2022
Titan, EUA, Court, Advertising, FDA, Class, I-Space (Chinese company), Insurance, Tobacco, Tiberius Claudius Verus

WHAT TO DO NEXT: To join the Veru class action, go to https://rosenlegal.com/submit-form/?case_id=9728 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Veru class action, go to https://rosenlegal.com/submit-form/?case_id=9728 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

VERU ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Veru Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, December 29, 2022
Prostate cancer, Standard of care, Tiberius Claudius Verus, Health minister, Aerospace, Telephone, P.C, COVID-19, Death, Form 10-Q, News, Breast, NDA, Trial of the century, Person, Fast track (FDA), Steiner, Patient, Mortality, EUA, Infection, Court, Safety, FDA, Prostate Cancer Foundation, Fast Track, Pharmaceutical industry, Renewable energy

Investors have until February 3, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until February 3, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Veru is primarily an oncology-based biopharmaceutical company that develops drugs for the management of breast and prostate cancers.
  • Veru also develops medicines forCOVID-19 and other diseases related to viral and acute respiratory distress syndrome (“ARDS”), and has two FDA-approved products for sexual health.
  • Veru had originally developed sabizabulin with the intention of using it as a treatment for prostate cancer.

VERU ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Veru Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, December 24, 2022
Prostate cancer, Standard of care, Tiberius Claudius Verus, Health minister, Aerospace, Telephone, P.C, COVID-19, Death, Form 10-Q, News, Breast, NDA, Trial of the century, Person, Fast track (FDA), Steiner, Patient, Mortality, EUA, Infection, Court, Safety, FDA, Prostate Cancer Foundation, Fast Track, Pharmaceutical industry, Renewable energy

Investors have until February 3, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until February 3, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Veru is primarily an oncology-based biopharmaceutical company that develops drugs for the management of breast and prostate cancers.
  • Veru also develops medicines forCOVID-19 and other diseases related to viral and acute respiratory distress syndrome (“ARDS”), and has two FDA-approved products for sexual health.
  • Veru had originally developed sabizabulin with the intention of using it as a treatment for prostate cancer.

ROSEN, A LEADING LAW FIRM, Encourages Veru, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action– VERU

Retrieved on: 
Saturday, December 24, 2022
Titan, EUA, Court, Advertising, FDA, Class, I-Space (Chinese company), Insurance, Tobacco, Tiberius Claudius Verus

WHAT TO DO NEXT: To join the Veru class action, go to https://rosenlegal.com/submit-form/?case_id=9728 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Veru class action, go to https://rosenlegal.com/submit-form/?case_id=9728 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Veru, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action– VERU

Retrieved on: 
Monday, December 19, 2022
Titan, EUA, Court, Advertising, FDA, Class, I-Space (Chinese company), Insurance, Tobacco, Tiberius Claudius Verus

WHAT TO DO NEXT: To join the Veru class action, go to https://rosenlegal.com/submit-form/?case_id=9728 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Veru class action, go to https://rosenlegal.com/submit-form/?case_id=9728 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

VERU ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Veru Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, December 17, 2022
Prostate cancer, P.C, Tiberius Claudius Verus, Prostate Cancer Foundation, Fast Track, Fast track (FDA), Breast, Mortality, Person, FDA, Safety, News, Death, Trial of the century, Court, Telephone, EUA, NDA, Aerospace, Form 10-Q, Infection, Health minister, Standard of care, COVID-19, Patient, Steiner, Pharmaceutical industry, Renewable energy

Investors have until February 3, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until February 3, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Veru is primarily an oncology-based biopharmaceutical company that develops drugs for the management of breast and prostate cancers.
  • Veru had originally developed sabizabulin with the intention of using it as a treatment for prostate cancer.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.